Organization · Holding Company
Nordicus Partners (OTCQB: NORD)
Nordicus Partners is a publicly traded holding company and business accelerator based in Beverly Hills, California, focused on empowering Nordic life sciences companies to succeed in the U.S. market. The firm targets high-growth opportunities in the life sciences sector, particularly in areas with unmet medical needs.
Overview
What Nordicus Partners (OTCQB: NORD) does
What Nordicus Partners (OTCQB: NORD) is
Nordicus Partners is a publicly traded holding company and business accelerator based in Beverly Hills, California, focused on empowering Nordic life sciences companies to succeed in the U.S. market. The firm targets high-growth opportunities in the life sciences sector, particularly in areas with unmet medical needs.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Holding Company
- Founded
- Founded in 1993
- Approximate age
- About 33 years
- Structured capabilities
- Funder
- Last reviewed
- April 24, 2026
Official channels
Find Nordicus Partners (OTCQB: NORD) elsewhere
Open the official website or a supported primary organization account.
Capability profile
Nordicus Partners (OTCQB: NORD) as a funder
Investment thesis
Acquire controlling or full stakes in Nordic preclinical-stage life-sciences companies, consolidate them under a US-listed vehicle, and provide capital, US-market access, and strategic counsel to advance their clinical pipelines.
Focus narrative
Nordicus Partners invests in transformative and scalable opportunities within the life sciences sector, specifically targeting high-growth markets with unmet medical needs. The organization focuses on early- and mid-stage companies, particularly in areas such as periodontal disease, oral leukoplakia, and central nervous system disorders. Their investment strategy includes a four-step value creation process: Scout and Accelerate, Acquire, and Exit.
Value beyond capital
Nordicus Partners provides capital, U.S. market access, and strategic counsel to advance the clinical pipelines of Nordic life sciences companies, leveraging its expertise to facilitate growth and success in the U.S. market.
Focus and fit
- Stages
- Pre-seed · Seed · Seed+ · Series A · Series A+
- Regions
- North AmericaEurope
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 2
Portfolio context
Nordicus Partners has a portfolio that includes notable companies such as: Orocidin: Developing treatments for aggressive periodontal disease. Bio-Convert: Focused on preventing oral leukoplakia, a potentially cancerous lesion in the mouth.
Common questions
What to know about Nordicus Partners (OTCQB: NORD)
Upseed classifies Nordicus Partners (OTCQB: NORD) under the Holding Company organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 24, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.